Wednesday, 05 August 2020 05:36

CBN releases healthcare fund limit for beneficiaries

Rate this item
(0 votes)

Central Bank of Nigeria has set N500m as the maximum grant that a beneficiary can obtain under Covid-19 healthcare intervention fund.

CBN disclosed this in the draft of its guidelines on healthcare research and development grant released on Tuesday.

Part of the report on grant limit said, “Research activities; maximum of N50m and development/manufacturing activities: maximum of N500m.”

The regulator said the disbursement under the scheme would be made to beneficiaries in tranches subject to approved milestones achieved.

According to the draft guidelines, the timeframe for research activities should not be more than two years from the date of the release of fund.

It added that the timeframe for development/manufacturing activities must not be more than one year from the date of release of fund.

CBN said it introduced the Healthcare Sector Research and Development Intervention Scheme as part of its policy response to Covid-19 pandemic.

It said the scheme would help strengthen the public healthcare system with innovative financing of research and development in new and improved drugs, vaccines and diagnostics of infectious diseases in Nigeria.

Specifically, it stated that the fund was designed to trigger intense national research and development activities to develop a Nigerian vaccine, drugs and herbal medicines against the spread of Covid-19 and any other communicable or non-communicable diseases.

CBN said the scheme was intended to boost domestic manufacturing of critical drugs and vaccines to ensure their sustainable domestic supply and reduce the bulk manufacturing costs of the drugs, herbal medicines and vaccines in Nigeria.

It further said, the objectives of the scheme include the provision of grants for research and development in new or revalidation of drug molecule, phyto-medicines and vaccines for the control, and prevention and treatment of infectious diseases in Nigeria.

It added that the scheme sought to boost domestic manufacturing of validated drugs (active pharmaceutical ingredients), herbal medicines and vaccines for the control, prevention and treatment of infectious diseases in Nigeria and reduce the nation’s dependence on other countries for these drugs and vaccines.

 

Punch

December 20, 2024

Naira expected to weaken further, says CBN business survey

Nigerian businesses anticipate further depreciation of the naira through early 2025, despite maintaining overall optimism…
December 20, 2024

Atiku questions alleged hack of NBS website, says timing suspicious

Former Vice President Atiku Abubakar has raised concerns over the recent claim that the website…
December 22, 2024

How to know if your memory lapses are serious or not

The older I get, the more panicked I become when something slips my mind. Is…
December 21, 2024

‘Professional Back-Scratchers’ charge up to $130 per hour

The Scratcher Girls is an unconventional relaxation therapy studio that charges clients up to $130…
December 21, 2024

NAFDAC busts illegal rice repackaging operations in Nasarawa, Abuja

The National Agency for Food and Drug Administration and Control (NAFDAC) has cracked down on…
December 22, 2024

Here’s the latest as Israel-Hamas war enters Day 443

Israel and Hamas appear close to a ceasefire deal. These are the sticking points Israel…
December 20, 2024

OpenAI launches voice and text access to ChatGPT through new phone service

OpenAI has introduced a novel way to interact with its popular ChatGPT artificial intelligence system…
December 17, 2024

Ademola Lookman named 2024 CAF Men’s Player of the year. These players won in other…

Ademola Lookman, the Super Eagles winger, was crowned the 2024 CAF Men’s Player of the…

NEWSSCROLL TEAM: 'Sina Kawonise: Publisher/Editor-in-Chief; Prof Wale Are Olaitan: Editorial Consultant; Femi Kawonise: Head, Production & Administration; Afolabi Ajibola: IT Manager;
Contact Us: [email protected] Tel/WhatsApp: +234 811 395 4049

Copyright © 2015 - 2024 NewsScroll. All rights reserved.